Abstract | OBJECTIVE: METHODS: RESULTS: The study group comprised 33 patients (16 assigned to receive raloxifene and 17 controls, mean +/- SD age 53.8 +/- 5.3 years). Age, body mass index, and baseline BMD values did not differ significantly between the 2 groups of patients. All patients were receiving low-dose prednisolone. After 12 months, femoral neck BMD (mean +/- SD -2.6 +/- 1.0%; P = 0.02) and lumbar spine BMD (-3.3 +/- 0.8%; P = 0.001) decreased significantly in the controls but not in the raloxifene group. No patient had a major flare of lupus, but mild/moderate flares occurred in 4 raloxifene-treated and 6 control patients (P = 0.79). The total area under the curve of SELENA-SLEDAI scores was not significantly different between the 2 groups. A significant increase in the high-density lipoprotein cholesterol level and a reduction in the low-density lipoprotein cholesterol level were observed in the raloxifene group but not in controls. One patient in the raloxifene group (6%) withdrew from the study because of hot flushes. No thromboembolic events were reported. CONCLUSION:
|
Authors | Chi Chiu Mok, Chi Hung To, Anselm Mak, Kwok Man Ma |
Journal | Arthritis and rheumatism
(Arthritis Rheum)
Vol. 52
Issue 12
Pg. 3997-4002
(Dec 2005)
ISSN: 0004-3591 [Print] United States |
PMID | 16320346
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Bone Density Conservation Agents
- Lipids
- Raloxifene Hydrochloride
|
Topics |
- Bone Density
(drug effects)
- Bone Density Conservation Agents
(administration & dosage, adverse effects)
- Bone Diseases, Metabolic
(complications, drug therapy, pathology)
- Female
- Femur Neck
(pathology)
- Humans
- Lipids
(blood)
- Lumbar Vertebrae
(pathology)
- Lupus Erythematosus, Systemic
(complications)
- Middle Aged
- Pilot Projects
- Postmenopause
- Raloxifene Hydrochloride
(administration & dosage, adverse effects)
- Treatment Outcome
|